R1507, an Anti-Insulin-Like growth Factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: Convergence at the IGF/IGFR/AKT axis

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Huang, Helen J ^a   Angelo, Laura S ^a   Rodon, Jordi ^a,b   Sun, Michael ^a   Kuenkele, Klaus Peter ^c   Parsons, Henrique A ^a   Trent, Jonathan C ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYBRID PROTEIN; PROTEIN KINASE B; R 1507; RECEPTOR ANTIBODY; RNA BINDING PROTEIN EWS; SMALL INTERFERING RNA; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR ANTIBODY; TRANSCRIPTION FACTOR FLI 1; UNCLASSIFIED DRUG; EWS FLI FUSION PROTEIN; EWS-FLI FUSION PROTEIN; IGFBP3 PROTEIN, HUMAN; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; R 1507 MONOCLONAL ANTIBODY; R-1507 MONOCLONAL ANTIBODY; SOMATOMEDIN; SOMATOMEDIN B RECEPTOR;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL ASSAY; CELL CLONE; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; EWING SARCOMA; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INTERNALIZATION; NUCLEOTIDE SEQUENCE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SARCOMA CELL; SIGNAL TRANSDUCTION; STEADY STATE; CELL PROLIFERATION; CELL STRAIN HEK293; CHEMISTRY; CLONOGENIC ASSAY; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; GENETIC POLYMORPHISM; GENETICS; METABOLISM; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; REPRODUCIBILITY; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; DOWN-REGULATION; HEK293 CELLS; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR II; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; POLYMORPHISM, GENETIC; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEIN C-FLI-1; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RECEPTOR, IGF TYPE 2; REPRODUCIBILITY OF RESULTS; RNA, SMALL INTERFERING; RNA-BINDING PROTEIN EWS; SARCOMA, EWING; SIGNAL TRANSDUCTION; SOMATOMEDINS; TRANSFECTION;

EID: 80053994190     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026060     Document Type: Article

References (50)

1. Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, et al. (2006) Ewing's Sarcoma Family of Tumors: Current Management. The Oncologist 11: 503-519.
2. Burchill SA, (2008) Molecular abnormalities in Ewing's sarcoma. Expert Rev Anticancer Ther 8: 1675-1687.
3. Janknecht R, (2005) EWS-ETS oncoproteins: The linchpins of Ewing tumors. Gene 363: 1-14.
4. Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, et al. (2010) A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-1 receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 16: 2458-2465.
5. Pavelic K, Bukovic D, Pavelic J, (2002) The role of insulin-like growth factor and its receptor in human tumors. Mol Med 8: 771-780.
6. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, et al. (2010) Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 11: 129-135.
7. Rodon J, DeSantos V, Ferry RJ Jr, Kurzrock R, (2008) Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials. Mol Cancer Ther 7: 2575-2588.
8. Tolcher AW, Sarantopoulos J, Patnik A, Papadopoulos K, Lin CC, et al. (2009) A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor type 1 receptor. J Clin Oncol 27: 5800-5807 Epub 2009 Sep 28.
9. Olmos D, Tan DS, Jones RL, Judson IR, (2010) Biological rationale and current experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J 16: 183-194.
10. Huang F, Greer A, Hurlburt W, Han X, Hafezi R, et al. (2009) The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 Inhibitors. Cancer Res 69: 161-170.
11. Toretsky JA, Thakar M, Eskenazi AE, Frantz CN, (1999) Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors. Cancer Res 59: 5745-5750.
12. Hung G, Li X, Faudoa R, Xeu Z, Kluwe L, et al. (2002) Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2. Int J Oncol 20: 475-482.
13. Jambhekar NA, Bagwan IN, Ghule P, SHet TM, Chinoy RF, et al. (2006) Comparative analysis of routine histology, immunohistochemistry, reverse transcriptase polymerase chain reaction, and fluorescence in situ hybridization in diagnosis of Ewing Family of Tumors. Arch Pathol Lab Med 130: 1813-1818.
14. Qian X, Jin L, Shearer BM, Ketterling RP, Jalal SM, et al. (2005) Molecular diagnosis of Ewing's Sarcoma/Primitive Neuroectodermal Tumor in formalin-fixed paraffin-embedded tissues by RT-PCR and fluorescence in situ hybridization. Diagn Mol Pathol 14: 23-28.
15. O'Sullivan M, Perlman EJ, Furman J, Humprhey PA, Dehner LP, et al. (2001) Visceral primitive peripheral neuroectodermal tumors: A clinicopathologic and molecular study. Human Pathology 32: 1109-1115.
16. Hu CK, McCall S, Madden J, Huang H, Clough R, et al. (2006) Loss of heterozygosity of M6P/IGF2R gene is an early event in the development of prostate cancer. Prostate Cancer and Prostatic Diseases 9: 62-67.
17. Mateo-Lozano S, Gokhale PC, Soldatenkov VA, Dritschilo A, Tirado OM, et al. (2006) Combined Transcriptional and Translational Targeting of EWS/FLI-1 in Ewing's Sarcoma. Clin Cancer Res 12: 6781-6790.
18. Meric F, Liao Y, Lee W-P, Pollock RE, Hung M-C, (2000) Adenovirus 5 Early Region 1A Does Not Induce Expression of the Ewing Sarcoma Fusion Product EWS-FLI1 in Breast and Ovarian Cancer Cell Lines. Clin Cancer Res 6: 3832-3836.
19. May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, et al. (1993) Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI-I for transformation. Proc Natl Acad Sci USA 90: 5752-5756.
20. Rikhof B, de Jong S, Suurmeijer AJH, Meijer C, van der Graaf WTA, (2009) The insulin-like growth factor system and sarcomas. J Pathol 217: 469-482.
21. Samani AA, Yakar S, LeRoith D, Brodt P, (2007) The Role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocrine Reviews 28: 20-47.
22. Savage SA, Woodson K, Walk E, Modi W, Liao J, et al. (2007) The National Osteosarcoma Etiology Study Group. Analysis of Genes Critical for Growth Regulation Identifies Insulin-like Growth Factor 2 Receptor Variations with Possible Functional Significance as Risk Factors for Osteosarcoma. Cancer Epidemiol Biomarkers Prev 16: 1667-1674.
23. Prieur A, Tirode F, Cohen P, Delattre O, (2004) EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 24: 7275-7283.
24. Cironi L, Riggi N, Provero P, Wolf N, Suva ML, et al. (2008) IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells. PLoS One 3: 2634-2647.
25. Hailey J, Maxwell E, Koukouras K, Bishop WR, Pachter JA, et al. (2002) Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol Cancer Ther 1: 1349-1353.
26. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, et al. (2008) Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 118: 2609-2619.
27. Wang Q, Greene MI, (2008) Mechanisms of resistance to ErbB-targeted cancer therapeutics. J Clin Invest 118: 2389-2392.
28. Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, et al. (2010) Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): Rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther 9: 2652-2664.
29. Yeh J, Litz J, Hauck P, Ludwig DL, Krystal GW, (2008) Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt. Lung Cancer 60: 166-174.
30. Chapuis N, Tamburini J, Cornillet-Lefebvre P, Gillot L, Bardet V, et al. (2009) Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica 95: 415-423.
31. Gong Y, Yao E, Shen R, Goel A, Arcila M, et al. (2009) High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 4: 1-11.
32. González I, Vicent S, de Alava H, Lecanda F, (2007) EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model. J Mol Med 85: 1015-1029.
33. Burchill SA, (2008) Molecular abnormalities in Ewing's sarcoma. Expert Rev Anticancer Ther 8: 1675-1687.
34. Parija T, Shirley S, Uma S, Rajalekshmy KR, Ayyappan S, et al. (2005) Type 1 (11; 22)(q24: q12) translocation is common in Ewing's sarcoma/peripheral neuroectodermal tumour in south Indian patients. J Biosci 30: 371-376.
35. Le Deley M-C, Delattre O, Schaefer K-L, Burchill SA, Koehler G, et al. (2010) Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol 28: 1982-1988.
36. Van Doorninck JA, Ji L, Schaub B, Shimada H, Wing MR, et al. (2010) Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: A report from the children's oncology group. J Clin Oncol 28: 1989-1994.
37. Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, et al. (2008) Addiction to elevated insulin-like growth factor I receptor and initial modulation of the Akt pathway define the responsiveness of Rhabdomyosarcoma to the targeting antibody. Cancer Res 68: 8039-8048.
38. Kolb EA, Kamara D, Zhang W, Lin J, Hingorani P, et al. (2010) R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer 55: 67-75.
39. Beltran PJ, Chung Y-A, Moody G, Mitchell P, Cajulis E, et al. (2011) Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. J Pharmacol & Exptl Therapeutics 337: 644-54.
40. Kong FM, Anscher MS, Washington MK, Killian JK, Jirtle RL, (2000) M6P/IGF2R is mutated in squamous cell carcinoma of the lung. Oncogene 19: 1572-1578.
41. Maki RG, (2010) Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 28: 4985-95.
42. Jamieson TA, Brizel DM, Killian JK, Oka Y, Jang HS, et al. (2003) M6P/IGF2R loss of heterozygosity in head and neck cancer associated with poor patient prognosis. BMC Cancer 3: 4-12.
43. Pavelic K, Kolak T, Kapitanovic S, Radosevic S, Spaventi S, et al. (2003) Gastric cancer: the role of insulin-like growth factor 2 (IGF 2) and its receptors (IGF 1R and M6-P/IGF 2R). J Pathol 201: 430-438.
44. Pavelic J, Krizanac S, Kapitanovic S, Pavelic L, Samarzija M, et al. (2005) The Consequences of Insulin-Like Growth Factors/Receptors Dysfunction in Lung Cancer. Am J Respir Cell Mol Biol 32: 65-71.
45. Pavelic J, Radakovic B, Pavelic K, (2007) Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma. Gyn Oncol 105: 727-735.
46. Kotsinas A, Evangelou K, Sideridou M, Kotzamanis G, Constantinides C, et al. (2008) The 3′ UTR IGF2R-A2/B2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer. Cancer Lett 259: 177-185.
47. Chao W, D'Amore PA, (2008) IGF2: Epigenetic regulation and role in development and disease. Cytokine & Growth Factor Reviews 19: 111-120.
48. Lee KW, Ma L, Yan X, Liu B, Zhang XK, et al. (2005) Rapid apoptosis induction by IGF-BP3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXRa/Nur77. J Biol Chem 280: 16942-8.
49. Herrero-Martin D, Osuna D, Ordonez JL, Sevillano V, Martins AS, et al. (2009) Stable interference of EWS/FLI-1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signaling and reveals TOPK as a new target. Br J Cancer 101: 80-90.
50. Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, et al. (2009) A small molecule blocking oncogenic protein EWS-FLI-1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 15: 750-757.